Latest "Fluorouracil Leukovorin bevacizumab Colorectal Cancer" News Stories

01:43 EDT 5th September 2015 | BioPortfolio

Here are the most relevant search results for "Fluorouracil Leukovorin bevacizumab Colorectal Cancer" found in our extensive news archives from over 250 global news sources.

More Information about Fluorouracil Leukovorin bevacizumab Colorectal Cancer on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Fluorouracil Leukovorin bevacizumab Colorectal Cancer for you to read. Along with our medical data and news we also list Fluorouracil Leukovorin bevacizumab Colorectal Cancer Clinical Trials, which are updated daily. BioPortfolio also has a large database of Fluorouracil Leukovorin bevacizumab Colorectal Cancer Companies for you to search.

Showing "Fluorouracil Leukovorin bevacizumab Colorectal Cancer" News Articles 1–25 of 16,000+

Extremely Relevant

Upfront FOLFOXIRI+bevacizumab followed by fluoropyrimidin and bevacizumab maintenance in patients with molecularly unselected metastatic colorectal cancer

New Agent Active in Refractory Metastatic Colorectal Cancer

Treatment with TAS-102 improved survival in heavily pretreated patients with metastatic colorectal cancer, including those refractory to fluorouracil. Medscape Medical News

FDA approves ramucirumab for metastatic colorectal cancer

The US Food and Drug Administration has approved ramucirumab (Cyramza) for use in combination with FOLFIRI for the treatment of patients with metastatic colorectal cancer (mCRC) whose disease has progressed on a first line bevacizumab-, oxaliplatin- ...

Lilly's Cryamza Receives Fourth FDA Approval

Eli Lilly and Company has received its fourth U.S. Food and Drug Administration (FDA) approval for Cryamza (ramucirumab). Cryamza (ramucirumab injection 10 mg/mL solution) is now also indicated in combination with Folfiri (irinotecan, folinic acid, and 5-fluorouracil) chemotherapy for the treatment of patients with metastatic colorectal cancer (mCRC) with disease progression on or after prior ther...

Global Colorectal Cancer Drugs Market 2015-2019

About Colorectal Cancer Colorectal cancer refers to malignancies that originate in the rectum or the colon. It is also known as bowel cancer. Formation of adenocarcinomas is the most common feature of colorectal cancer. The cancer starts as a polyp in th...

March Is National Colorectal Cancer Awareness Month

OMNI Health Media (OMNI) announces the launch of colorectal cancer programs for national colorectal cancer awareness month. As the month of March brings colorectal cancer into focus, it’s time to increase public understanding of the disease, includ...


New indication for bevacizumab in cervical cancer

Bevacizumab, a monoclonal antibody most commonly used to treat bowel, breast and kidney cancer, may soon receive marketing authorisation for cervical cancer. The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP)...

Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer

How aspirin fights colorectal cancer

Taking aspirin reduces a person's risk of colorectal cancer, but the molecular mechanisms involved have remained unknown until a recent discovery. discovered that aspirin might exert its chemopreventive activity against colorectal cancer, at least pa...

New approach holds promise for earlier, easier detection of colorectal cancer

(California Institute of Technology) Chemists at Caltech have developed a new sensitive electrochemical technique capable of detecting colorectal cancer in tissue samples -- a method that could one day be used in clinical settings for the early diagn...

Effects of aspirin on colorectal cancer

In this interview Dr Din, a Cancer Research UK Clinician Scientist and Honorary Consultant Colorectal Surgeon, discusses her work looking at the use of aspirin as a chemopreventative agent in colorectal cancer (CRC) at the 2015 Scientific Conference ...

Colorectal cancer: Back to the stroma—the real villain in colorectal cancer?

The cells responsible for particular gene signatures in large-scale microarray studies of colorectal cancer have now been revealed. In doing so, the gene signature associated with poor prognosis is shown to be predominantly of stromal origin.

Advances in the care of patients with mucinous colorectal cancer

Mucinous colorectal cancer has, in the past, been associated with inferior responses to treatment, and worse patient outcomes compared with other colorectal cancer subtypes; although, this situation has improved in the past 10–15 years. In this Rev...

Adding Bevacizumab to Chemotherapy Improves PFS in Endometrial Cancer

The addition of bevacizumab to carboplatin/paclitaxel chemotherapy increases progression-free survival in advanced/recurrent endometrial cancer patients.

Researchers examine risk factors/patient outcomes associated with colorectal cancer

About 20 percent of colorectal cancer patients have cancers that have spread beyond the colon at the time of their diagnosis. In a new study, researchers provide a detailed comparison of patient outcomes associated with synchronous and sequential col...

Biothera Immunotherapy Combination Results in Tumor Reduction During Maintenance Phase of Non-Small Cell Lung Cancer Study

The combination of the investigational cancer immunotherapy Imprime PGG and the monoclonal antibody bevacizumab achieved additional meaningful reductions in tumor burden during the maintenance phase of Biothera’s recent phase 2 clinical trial in non-small cell lung cancer (NSCLC). The new data will be released today at the European Lung Cancer Conference. ...

Bio-marker set forms the basis for new blood test to detect colorectal cancer

SOURCE MARCH 30, 2015 Colorectal cancer is the third most common form of cancer globally and the second most common cause of cancer deaths. The chance of a cure is high if the cancer is detected early enough, but early detection is not a given. Researchers from VIB and KU […]

AAPS PharmSciTech: Topical Delivery of 5-Fluorouracil from Pheroid™ Formulations and the In Vitro Efficacy Against Human Melanoma

Type: Original PaperDrug delivery vehicles can influence the topical delivery and the efficacy of an active pharmaceutical ingredient (API). In this study, the influence of Pheroid™ technology, which is a unique colloidal drug delivery system, on t...

Biomarker set forms the basis for new blood test to detect colorectal cancer

Colorectal cancer is the third most common form of cancer globally and the second most common cause of cancer deaths. The chance of a cure is high if the cancer is detected early enough, but early detection is not a given. Researchers from VIB and KU...

Patients with lowest BMI have shortest survival in pooled analysis of bev in mCRC

(European Society for Medical Oncology) Patients with the lowest body mass index had the shortest overall survival in an analysis of bevacizumab studies in metastatic colorectal cancer presented for the first time at the ESMO 17th World Congress on G...

Neoadjuvant Bevacizumab Shows Promise in HER2-Negative Breast Cancer

A phase III trial demonstrated efficacy and safety of adding bevacizumab (Avastin) to standard neoadjuvant chemotherapy in patients with HER2-negative breast cancer.

March for colorectal cancer awareness

A 75-year-old woman with progressive constipation. An 82-year-old man with unexplained anemia. A 39-year-old mother of two with intermittent blood in her stool. These are three of my patients. And sadly, they are three of nearly 150,000 Americans diagnosed with colorectal cancer every year. March is National Colorectal Cancer Awareness Month for good reason. In […]

Mouse models of human colorectal cancer generated through chemokine targeting

by ecancer reporter Clare Sansom Xenografts of human colorectal cancer (CRC) cells into mouse models have yielded many important insights into the pathogenesis of this disease and its treatment. However, none of the mouse models of colorectal canc...

Reaching '80 percent by 2018' would prevent more than 20,000 colorectal cancer deaths per year

(American Cancer Society) Increasing colorectal cancer screening rates to 80 percent by 2018 would prevent an additional 21,000 colorectal cancer deaths per year by 2030, according to a new study.

Fluorouracil Cream May Squelch Actinic Keratoses (CME/CE)

(MedPage Today) -- Fluorouracil beats out control cream in long-term randomized trial.


News Quicklinks